ECSP099629A - Composición farmacéutica - Google Patents

Composición farmacéutica

Info

Publication number
ECSP099629A
ECSP099629A EC2009009629A ECSP099629A ECSP099629A EC SP099629 A ECSP099629 A EC SP099629A EC 2009009629 A EC2009009629 A EC 2009009629A EC SP099629 A ECSP099629 A EC SP099629A EC SP099629 A ECSP099629 A EC SP099629A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
sorbitol
tablet
angiotensin
surface area
Prior art date
Application number
EC2009009629A
Other languages
English (en)
Inventor
Frieder Ulrich Maerz
Ruediger Thomas
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38179677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ECSP099629A publication Critical patent/ECSP099629A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un comprimido o capa de comprimido farmacéutico que comprende el antagonista del receptor de angiotensina II telmisartán en forma amorfa, un agente básico y sorbitol, caracterizado porque el sorbitol tiene un área de superficie específica de entre 0,75-3,5 m²/g.
EC2009009629A 2007-03-14 2009-09-11 Composición farmacéutica ECSP099629A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07104157A EP1970053A1 (en) 2007-03-14 2007-03-14 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ECSP099629A true ECSP099629A (es) 2009-10-30

Family

ID=38179677

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009629A ECSP099629A (es) 2007-03-14 2009-09-11 Composición farmacéutica

Country Status (35)

Country Link
US (1) US20100143465A1 (es)
EP (2) EP1970053A1 (es)
JP (1) JP5742045B2 (es)
KR (1) KR101503674B1 (es)
CN (1) CN101641084B (es)
AR (1) AR065726A1 (es)
AT (1) ATE493119T1 (es)
AU (1) AU2008225754B2 (es)
BR (1) BRPI0808797A2 (es)
CA (1) CA2680608C (es)
CL (1) CL2008000733A1 (es)
CO (1) CO6220927A2 (es)
CY (1) CY1111350T1 (es)
DE (1) DE602008004217D1 (es)
DK (1) DK2120884T3 (es)
EA (1) EA018574B1 (es)
EC (1) ECSP099629A (es)
ES (1) ES2358770T3 (es)
HR (1) HRP20110012T1 (es)
IL (1) IL200125A (es)
MA (1) MA31251B1 (es)
MX (1) MX2009009201A (es)
MY (1) MY145089A (es)
NZ (1) NZ580185A (es)
PE (1) PE20090165A1 (es)
PL (1) PL2120884T3 (es)
PT (1) PT2120884E (es)
RS (1) RS51584B (es)
SI (1) SI2120884T1 (es)
TN (1) TN2009000371A1 (es)
TW (1) TWI406678B (es)
UA (1) UA96982C2 (es)
UY (1) UY30961A1 (es)
WO (1) WO2008110599A1 (es)
ZA (1) ZA200905224B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
WO2009058950A2 (en) * 2007-10-30 2009-05-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide
EP2291177A2 (en) 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
CZ2008469A3 (cs) * 2008-07-31 2009-10-29 Zentiva, A. S. Telmisartan tablety
GB0822171D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Temisartan formulations
SG176585A1 (en) * 2009-05-20 2012-01-30 Boehringer Ingelheim Vetmed Pharmaceutical oral telmisartan solution
MX377674B (es) * 2012-03-19 2025-03-11 Althera Life Sciencies Llc Formulacion de tableta oral solida de rosuvastatina de liberacion inmediata y metformina de liberacion prolongada.
JP6344678B2 (ja) * 2013-09-27 2018-06-20 キョーリンリメディオ株式会社 テルミサルタン含有製剤及びその製造方法
JP6096328B2 (ja) * 2014-02-10 2017-03-15 富士フイルム株式会社 口腔内崩壊錠
BE1021954B1 (nl) * 2014-06-05 2016-01-28 Syral Belgium Nv Samenstelling van sorbitol met lage friabiliteit
FR3023128B1 (fr) 2014-07-01 2017-11-10 Roquette Freres Nouvelle composition edulcorante
JP5871294B1 (ja) * 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
CN106420739A (zh) * 2016-10-31 2017-02-22 扬子江药业集团四川海蓉药业有限公司 一种替米沙坦氨氯地平双层片及其制备方法
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN109316451B (zh) * 2017-07-31 2022-07-01 武汉朗来科技发展有限公司 治疗高血压和相关疾病的口服固体制剂
FI3787596T3 (fi) 2018-05-02 2025-09-29 Ferring Bv Parannettuja farmaseuttisia formulaatioita
EP3996709A1 (en) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan for the treatment of hypertension in dogs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3245170A1 (de) * 1982-12-07 1984-06-07 Merck Patent Gmbh, 6100 Darmstadt Verbesserter sorbit, verfahren zur herstellung und verwendung
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
FR2787110B1 (fr) * 1998-12-11 2001-02-16 Roquette Freres Sorbitol pulverulent et son procede de preparation
HRP20040649B1 (en) * 2002-01-16 2012-12-31 Boehringer Ingelheim Pharma Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
RS53141B (sr) * 2004-11-05 2014-06-30 Boehringer Ingelheim International Gmbh Dvoslojna tableta koja sadrži telmisartan i amlodipin
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
EA200701159A1 (ru) * 2004-12-17 2007-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Комбинированное лекарственное средство, включающее телмисартан и гидрохлортиазид

Also Published As

Publication number Publication date
CO6220927A2 (es) 2010-11-19
TN2009000371A1 (fr) 2010-12-31
KR101503674B1 (ko) 2015-03-18
UY30961A1 (es) 2008-10-31
JP2010530844A (ja) 2010-09-16
CN101641084B (zh) 2013-04-10
PT2120884E (pt) 2011-02-10
UA96982C2 (ru) 2011-12-26
ES2358770T3 (es) 2011-05-13
EP2120884A1 (en) 2009-11-25
EP1970053A1 (en) 2008-09-17
BRPI0808797A2 (pt) 2013-01-15
HK1140692A1 (en) 2010-10-22
RS51584B (sr) 2011-08-31
CL2008000733A1 (es) 2008-07-04
EA018574B1 (ru) 2013-09-30
CN101641084A (zh) 2010-02-03
ZA200905224B (en) 2010-04-28
TWI406678B (zh) 2013-09-01
ATE493119T1 (de) 2011-01-15
EA200901169A1 (ru) 2010-04-30
KR20090119998A (ko) 2009-11-23
IL200125A0 (en) 2010-04-15
AU2008225754A1 (en) 2008-09-18
DK2120884T3 (da) 2011-02-07
NZ580185A (en) 2011-11-25
CA2680608C (en) 2015-06-16
AU2008225754B2 (en) 2013-04-04
PL2120884T3 (pl) 2011-05-31
PE20090165A1 (es) 2009-03-31
AR065726A1 (es) 2009-06-24
CA2680608A1 (en) 2008-09-18
MX2009009201A (es) 2009-09-08
HRP20110012T1 (hr) 2011-02-28
IL200125A (en) 2012-01-31
EP2120884B1 (en) 2010-12-29
TW200900095A (en) 2009-01-01
CY1111350T1 (el) 2015-08-05
MA31251B1 (fr) 2010-03-01
MY145089A (en) 2011-12-30
DE602008004217D1 (de) 2011-02-10
WO2008110599A1 (en) 2008-09-18
SI2120884T1 (sl) 2011-04-29
US20100143465A1 (en) 2010-06-10
JP5742045B2 (ja) 2015-07-01

Similar Documents

Publication Publication Date Title
UY30961A1 (es) Comprimido famacéutico, capa de comprimido comprendiendo ingrediente activo telmisartan, un agente basico y sorbitol, proceso de preparacion y aplicaciones,
CL2008000610A1 (es) Composicion en forma de dosificacion transdermica o transmucosa que comprende una relacion en peso de buprenorfina a naloxona entre 2,1:1 y 8:1, util para el tratamiento del dolor.
CL2007001902A1 (es) Compuestos derivados de piridina sustituidas; composicion farmaceutica; y uso en el tratamiento de un trastorno de agregacion de plaquetas.
NO343776B1 (no) Forbindelse som modulerer farmakokinetikkegenskaper til terapeutika, dens anvendelse i terapi og farmasøytisk sammensetning derav.
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
EP2475427A4 (en) ACTRIIB ANTAGONISTS, THEIR DOSAGE AND APPLICATIONS THEREOF
CL2007003718A1 (es) Compuestos macrociclos, inhibidores selectivos del factor viia de coagulacion de serinaproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de un trastorno tromboembolico.
CL2007001724A1 (es) Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
MX2012001359A (es) Articulos para el cuidado oral.
BRPI0912161A2 (pt) composição farmacêutica na forma de um tablete
CL2007002167A1 (es) Compuestos derivados de indol, antagonistas iap; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de cancer.
CL2013001943A1 (es) Uso de un agonista opioide y un antagonista opioide para preparar una forma farmaceutica para el tratamiento de la enfermedad de parkinson y/o al menos un sintoma de la misma.
BRPI0616703A2 (pt) forma de dosagem farmacêutica
DE602007010797D1 (de) Pharmazeutische zusammensetzungen mit rosuvastatin-calcium
CL2007002218A1 (es) Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
CL2012000333A1 (es) Antagonista del receptor de la endotelina útil en la prevención o el tratamiento de metástasis cerebral en combinación con un agente de quimioterapia citotóxico, radioterapia o ambos; su uso para inhibir protección mediada por astrocito de una célula cerebral metastasica de una muerte celular inducida por quimioterapia citotóxica; y su uso para tratar un tumor cerebral metastásico.
PA8809601A1 (es) Combinación anti-retroviral
BRPI0816236A2 (pt) Peptídeo cdh3 e agente medicinal contendo o mesmo
CL2007001752A1 (es) Compuesto 4-[5(2-amino-etansulfonil)-isoquinolin-7-il]-fenolo una sal farmaceuticamente aceptable o un hidrato o la sal del mismo;composicion farmaceutica que comprende a dicho compuesto,composicion farmaceutica liofilizada;y uso del compuesto como antineiplasico y/o antiviral.
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2013002789A1 (es) El compuesto (2-hidroxi-etil)-amida del ácido 1-{5-fenil-4-[(piridin-2-ilmetil)-amino]-tieno[2,3-d]pirimidin-2-il}-piperidin-3-carboxilico, inhibidor del canal de potasio; composicion farmaceutica; y su uso en el tratamiento o la prevencion de la arritmias.